1. National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021SARS-CoV-2 antibody prevalence in school children
- Author
-
Powell, Annabel A, Ireland, Georgina, Leeson, Rebecca, Lacey, Andrea, Ford, Ben, Poh, John, Ijaz, Samreen, Shute, Justin, Cherepanov, Peter, Tedder, Richard, Bottomley, Christian, Dawe, Fiona, Mangtani, Punam, Jones, Peter, Nguipdop-Djomo, Patrick, Ladhani, Shamez N, Group, COVID-19 Schools Infection Survey, Ahmad, Shazaad, Baawuah, Frances, Beckmann, Joanne, Brent, Andrew, Brent, Bernadette, Garstang, Joanna, Okike, Ifeanyichukwu O, Brown, Kevin, Ramsay, Mary, Bonell, Chris, Cook, Sarah, Warren-Gash, Charlotte, Phelan, Jody, Hargreaves, James, Langan, Sinead, Sundaram, Neisha, McClenaghan, Elliot, McKay, Gillian, Edmunds, John, and Fine, Paul
- Subjects
Genome Integrity & Repair ,Cell Cycle & Chromosomes ,Biochemistry & Proteomics ,Structural Biology & Biophysics - Abstract
BACKGROUND: SARS-CoV-2 infection rates are likely to be underestimated in children because of asymptomatic or mild infections. We aim to estimate national and regional prevalence of SARS-CoV-2 antibodies in primary (4-11-year-olds) and secondary (11-18-year-olds) school children between 10 November and 10 December 2021. METHODS: Cross-sectional surveillance in England using two stage sampling, firstly stratifying into regions and selecting local authorities, then selecting schools according to a stratified sample within selected local authorities. Participants were sampled using a novel oral fluid validated assay for SARS-CoV-2 spike and nucleocapsid IgG antibodies. RESULTS: 4,980 students from 117 state-funded schools (2,706 from 83 primary schools, 2,274 from 34 secondary schools) provided a valid sample. After weighting for age, sex and ethnicity, and adjusting for assay accuracy, the national prevalence of SARS-CoV-2 antibodies in primary school students, who were all unvaccinated, was 40.1% (95%CI; 37.3-43.0). Antibody prevalence increased with age (p
- Published
- 2023
- Full Text
- View/download PDF